You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
The recent surge in publications on Parkinson’s disease related exercise has left many patients and doctors ill equipped to implement these types of programs for individual sufferers. Most of the exercise trials in Parkinson’s disease have revealed meaningful benefits both in Parkinson’s specific symptoms, and in quality of life. Though we have yet to sort out the best types of exercise regimes, the mot appropriate frequency of exercise, and the optimal intensity of therapy for any individual patient, there is unfortunately an even larger issue facing the field. Many people suffering from Parkinson’s disease simply stated do not exercise. Understanding the barriers preventing implementation of a regular Parkinson’s disease exercise program will be important for both prescribing clinicians and for patients.
In the January 3rd issue of the journal Physical Therapy, Ellis and colleagues explored the barriers to exercise in community dwelling people with Parkinson’s disease. The authors studied 260 Parkinson’s disease patients and compared exercisers to non-exercisers. The patients were asked to complete the barriers subscale of the Physical Fitness and Exercise Activity Levels of Older Adults Scale. The study revealed that in people who did not exercise, there was a low expectation for positive benefit. The non-exercise group also was concerned about the amount of time needed per day to initiate such a program, as well as the fall risk associated with exercise.
Making our clinicians and our patients aware of the barriers to implementing exercise programs for Parkinson’s disease will aid us in overcoming the issues unearthed by Ellis et. al. There will, in the near future, likely be more Parkinson’s specific research studies that will shed even more light on this issue. In the man time, education will play a pivotal role in facilitating the implementation of exercise plans, and health care practitioners as well as family members should be prepared to present Parkinson’s disease patients with recent scientific data supporting the use of exercise. A higher level conversation about exercise, citing its proven benefits, has an enhanced potential to reverse some of the low expectations expressed by many Parkinson’s sufferers. Additionally, it should be stressed to patients that consistent daily exercise may be performed in small aliquots of time (30-60 minutes a day), and in many cases within the home setting. Finally, there are many exercises that can be performed safely without increasing the fall risk. Involvement of a physical therapist and a care partner can be useful in setting up a safe, and consistent home-based or gym-based program.
As more studies clarify the types of exercise we should be prescribing for individual patients, more clinicians will need to develop strategies to defeat the barriers to implementing exercise programs in Parkinson’s disease. Exercise is likely to improve the quality of life for most Parkinson’s disease sufferers, but we must meet the meet the public health challenge to get it adopted, and get it embraced by the Parkinson’s disease community.
Ellis T, Boudreau JK, Deangelis TR, Brown LE, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Dibble LE. Barriers to Exercise in People With Parkinson Disease. Phys Ther. 2013 Jan 3. [Epub ahead of print] PubMed PMID: 23288910.
Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011 Jul 19;77(3):288-94. doi: 10.1212/WNL.0b013e318225ab66. Review. PubMed PMID: 21768599; PubMed Central PMCID: PMC3136051.
Posted: 2/4/2013 12:34:30 PM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease